BMY BRISTOL MYERS SQUIBB CO

NYSE bms.com


$ 46.53 $ -1.46 (-3.04 %)    

Friday, 14-Nov-2025 14:19:30 EST
QQQ $ 610.15 $ 10.59 (1.77 %)
DIA $ 472.69 $ 1.34 (0.28 %)
SPY $ 673.16 $ 7.71 (1.16 %)
TLT $ 88.97 $ -0.82 (-0.91 %)
GLD $ 376.57 $ 3.68 (0.99 %)
$ 48.63
$ 48.10
$ 46.56 x 300
$ 46.58 x 300
$ 46.13 - $ 48.33
$ 42.38 - $ 61.00
14,502,621
na
99B
$ 0.25
$ 16.39
TBD
na
na ($ 0.05)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-30-2025 09-30-2025 10-Q
2 07-31-2025 06-30-2025 10-Q
3 04-24-2025 03-31-2025 10-Q
4 02-12-2025 12-31-2024 10-K
5 10-31-2024 09-30-2024 10-Q
6 07-26-2024 06-30-2024 10-Q
7 04-25-2024 03-31-2024 10-Q
8 02-13-2024 12-31-2023 10-K
9 10-26-2023 09-30-2023 10-Q
10 07-27-2023 06-30-2023 10-Q
11 04-27-2023 03-31-2023 10-Q
12 02-14-2023 12-31-2022 10-K
13 10-26-2022 09-30-2022 10-Q
14 07-27-2022 06-30-2022 10-Q
15 04-29-2022 03-31-2022 10-Q
16 02-09-2022 12-31-2021 10-K
17 10-27-2021 09-30-2021 10-Q
18 07-28-2021 06-30-2021 10-Q
19 04-29-2021 03-31-2021 10-Q
20 02-10-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 02-24-2020 12-31-2019 10-K
25 10-31-2019 09-30-2019 10-Q
26 07-25-2019 06-30-2019 10-Q
27 04-25-2019 03-31-2019 10-Q
28 02-25-2019 12-31-2018 10-K
29 10-25-2018 09-30-2018 10-Q
30 07-26-2018 06-30-2018 10-Q
31 04-26-2018 03-31-2018 10-Q
32 02-13-2018 12-31-2017 10-K
33 10-26-2017 09-30-2017 10-Q
34 07-27-2017 06-30-2017 10-Q
35 04-27-2017 03-31-2017 10-Q
36 02-21-2017 12-31-2016 10-K
37 10-27-2016 09-30-2016 10-Q
38 07-28-2016 06-30-2016 10-Q
39 04-28-2016 03-31-2016 10-Q
40 02-12-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 tech-rebounds-after-selloff-bitcoin-craters-to-97000-whats-moving-markets-friday

Investors stepped back into beaten-down tech names Friday, with the Nasdaq 100 rising 0.6% by midday in New York, staging a mod...

 bristol-myers-faces-another-trial-disappointment-as-heart-drug-milvexian-fails-to-show-efficacy

Bristol Myers and Johnson & Johnson ended the Librexia ACS trial after an interim review showed low efficacy, while AF and ...

 pfizer-seeks-to-exit-biontech-investment-after-lucrative-covid-vaccine-run

Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine part...

 sarah-cannon-research-institute-expands-partnership-with-bristol-myers-squibb-to-accelerate-development-of-cancer-therapies-enhance-access-to-clinical-studies

Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-bas...

Core News & Articles

Milestone payment reflects continued progress under strategic research collaboration addressing high-need patient populationsFD...

 jim-cramer-is-backing-off-bristol-myers-but-these-2-chinese-stocks-are-good

"Mad Money" host Jim Cramer discusses Bristol-Myers Squibb, Baidu, Alibaba, Brinker and New Era Energy & Digital.

 bristol-myers-squibb-prices-5-billion-senior-unsecured-notes-offering-via-irish-subsidiary-across-five-tranches-due-2030-2055

Bristol Myers Squibb (NYSE:BMY) today announced that it has priced a public offering (the "Offering") of senior unsecur...

 biontech-sees-higher-2025-sales-driven-by-bristol-myers-partnership

BioNTech reports a Q3 loss but boosts 2025 revenue forecast to €2.6–2.8 billion, driven by Bristol Myers collaboration and cost...

 cleveland-cliffs-meta-and-rocket-on-cnbcs-final-trades

Cleveland-Cliffs shares gained 1.4% to close at $12.43 on Friday while Bristol-Myers Squibb shares gained 1% to close at $46.07.

 bristol-myers-squibb-presents-new-long-term-and-real-world-data-from-cardiovascular-portfolio-at-ahass-2025

Multiple real-world analyses and an analysis of long-term extension data reinforce the well-established efficacy and safety pro...

 bristol-myers-squibb-launches-7b-debt-buyback-program-to-manage-outstanding-notes

Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol Myers Squibb" or the "Offeror"), announced the commencement o...

 bristol-myers-new-treatments-drive-q3-beat--and-the-companys-raising-its-outlook

Bristol Myers beats Q3 forecasts with $12.22 billion revenue and a higher 2025 sales outlook, driven by strong demand for Reblo...

 meta-tumbles-10-google-marks-historic-rally-whats-moving-markets-thursday

Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the me...

 bristol-myers-squibb-narrows-fy2025-adj-eps-guidance-from-635-665-to-640-660-vs-638-est-raises-fy2025-sales-guidance-from-46500b-47500b-to-47500b-48000b-vs-47332b-est

Bristol-Myers Squibb (NYSE:BMY) narrows FY2025 Adj EPS guidance from $6.35-$6.65 to $6.40-$6.60 vs $6.38 analyst estimate. Rais...

 bristol-myers-squibb-q3-adj-eps-163-beats-151-estimate-sales-12222b-beat-11814b-estimate

Bristol-Myers Squibb (NYSE:BMY) reported quarterly earnings of $1.63 per share which beat the analyst consensus estimate of $1....

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION